Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast
03/09/2021 - 04:01 PM
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development.
A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com . An archived version of the webcast will be available on Infinity's website for 30 days.
About Infinity and eganelisib
Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com .
Opdivo® is a registered trademark of Bristol Myers Squibb.
® is a registered trademark of Genentech, Inc.
® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
® is a registered trademark of Genentech, Inc.
® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005959/en/
Infinity Pharmaceuticals Inc.
INFI Rankings
N/A Ranked by Stock Gains
INFI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About INFI
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
